Tuesday, Roche Holding AG (RHHBY) announced a research partnership with Ascidian Therapeutics for the advancement of Ascidian's RNA exon editing therapeutics aimed at neurological diseases.
As part of the agreement, Ascidian will grant Roche exclusive rights to utilize its RNA exon editing technology for specific undisclosed neurological targets. While Ascidian will lead the discovery and some preclinical work in conjunction with Roche. Additional preclinical tasks, clinical development, production, and marketing will be overseen by Roche.
Ascidian is set to receive an initial payment of $42 million and stands to earn up to $1.8 billion in milestone payments for research, clinical trials, and commercial achievements, in addition to royalties from global sales.
Furthermore, Ascidian retains the flexibility to pursue projects targeting other neurological conditions independently or with different partners according to the terms of the agreement.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.